Conclusion. Administration of preprandi- al exenatide by s.c. injection resulted in dose-proportional exenatide pharmacoki- netics and antidiabetic pharmacodynamic activity. At doses ranging from 0.02 to 0.2 Âµg/kg, exenatide dose-dependently re- duced postprandial plasma glucose excur- sion by insulinotropism, suppression of plasma glucagon, and slowing of gastric emptying. Index terms: Antidiabetic agents; Blood levels; Diabetes mellitus; Dosage; Drug ad- ministration routes; Exenatide; Gastric emptying; Mechanism of action; Pharmaco- dynamics; Pharmacokinetics; Toxicity Am J Health-Syst Pharm. 2005; 62:173-81The increasing number of people worldwide with type 2 diabetesmellitus has major implications for both health care systems and theaffected individuals, particularly be-cause of the increased potential formicrovascular and macrovascularcomplications. Results from theUnited Kingdom Prospective Diabe-tes Study (UKPDS) showed that a re-duction in glycosylated hemoglobin(HbA